<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39413075</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The value of using COVID-19 antibody tests as a potential approach to prioritize vaccination delivery.</ArticleTitle><Pagination><StartPage>e0311881</StartPage><MedlinePgn>e0311881</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0311881</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0311881</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The highly contagious novel COVID-19 virus has demonstrated a great challenge for healthcare workers (HCWs) worldwide. One of these challenges is the availability of vaccines in some countries or societies, especially in the early stages of the pandemic.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to determine the level of natural immunity against COVID-19 infection among HCWs exposed to COVID-19 at the early stages of the pandemic and build a model to determine the groups that can benefit more from the scarce vaccination resources.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study took place between January and March 2021, after the first waves of the COVID-19 pandemic, before spreading the variants of concern, such as the UK variant (Alpha B.1.1.7), and before starting the vaccine campaigns. This cross-sectional study collected serum samples from 251 vulnerable HCWs. The samples were tested for IgG antibodies against COVID-19 using commercial kits. The demographics and clinical characteristics of the participants were recorded using face-to-face interviews.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19 IgG antibodies were detected in more than 40% of HCWs before vaccination. Those HCWs should have less priority than those without COVID-19 IgG. The seroprevalence of COVID-19 was higher in male HCWs and among nurses. There was no association between the participants' immunity and smoking status or different blood groups. Most HCWs reported being infected with the virus during the first wave, mainly at the end of 2020. A limited number of HCWs reported infections between January 2021 and March 2021. All HCWs eventually received the COVID-19 vaccine, ignoring being previously infected.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The reported results emphasize the value of using immunity tests to prioritize the groups that may benefit the most from the limited vaccines, especially in developing countries with scarce resources where those with COVID-19 IgG antibodies should have less priority for the COVID-19 vaccine. The present results indicate that up to 40% of the delivered vaccines to HCWs who had COVID-19 antibodies could be prioritized more wisely in future pandemics.</AbstractText><CopyrightInformation>Copyright: © 2024 Alrabadi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alrabadi</LastName><ForeName>Nasr</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeidat</LastName><ForeName>Haneen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Razan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alyassin</LastName><ForeName>Noor</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzoubi</LastName><ForeName>Karem H</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-2808-5099</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeidat</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shteiwi</LastName><ForeName>Saif M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, The University of Jordan, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Rabadi</LastName><ForeName>Daher</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Community and Mental Health Nursing, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Faouri</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Community and Mental Health Nursing, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>NO authors have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39413075</ArticleId><ArticleId IdType="pmc">PMC11482680</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0311881</ArticleId><ArticleId IdType="pii">PONE-D-24-02700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254–66. doi: 10.1016/j.cca.2020.05.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.05.044</ArticleId><ArticleId IdType="pmc">PMC7256510</ArticleId><ArticleId IdType="pubmed">32474009</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Respiratory M. COVID-19 transmission-up in the air. Lancet Respir Med. 2020;8(12):1159. doi: 10.1016/S2213-2600(20)30514-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30514-2</ArticleId><ArticleId IdType="pmc">PMC7598535</ArticleId><ArticleId IdType="pubmed">33129420</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al.. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. Febs j. 2020;287(17):3633–50. doi: 10.1111/febs.15375</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15375</ArticleId><ArticleId IdType="pmc">PMC7283703</ArticleId><ArticleId IdType="pubmed">32446285</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al.. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. doi: 10.1016/j.tmaid.2020.101623</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101623</ArticleId><ArticleId IdType="pmc">PMC7102608</ArticleId><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al.. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428–42. doi: 10.1177/01410768211032850</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al.. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022;5(5):Cd013665. doi: 10.1002/14651858.CD013665.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013665.pub3</ArticleId><ArticleId IdType="pmc">PMC9121352</ArticleId><ArticleId IdType="pubmed">35593186</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395(10228):931–4. doi: 10.1016/S0140-6736(20)30567-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30567-5</ArticleId><ArticleId IdType="pmc">PMC7158572</ArticleId><ArticleId IdType="pubmed">32164834</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Coronavirus disease (COVID-2019) situation reports 2020 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation></Reference><Reference><Citation>CDC. About COVID-19 Epidemiology, Investigating COVID-19: The Science Behind CDC’s Response
2022.  [cited 2024 Jan 11th]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/about-epidemiology/index.html.</Citation></Reference><Reference><Citation>Melnick ER, Ioannidis JPA. Should governments continue lockdown to slow the spread of covid-19? Bmj. 2020;369:m1924. doi: 10.1136/bmj.m1924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1924</ArticleId><ArticleId IdType="pubmed">32493767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gapen M, Millar J, Uruçi B, Sriram P. Assessing the effectiveness of alternative measures to slow the spread of COVID-19 in the United States. Covid Economics. 2020;40:46–75.</Citation></Reference><Reference><Citation>Glynn MA. ‘15 Days to Slow the Spread’: Covid‐19 and Collective Resilience. Journal of Management studies. 2021;58(1):265.</Citation></Reference><Reference><Citation>Courtney EP, Felig RN, Goldenberg JL. Together we can slow the spread of COVID‐19: The interactive effects of priming collectivism and mortality salience on virus‐related health behaviour intentions. British Journal of Social Psychology. 2022;61(1):410–31. doi: 10.1111/bjso.12487</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjso.12487</ArticleId><ArticleId IdType="pmc">PMC8420273</ArticleId><ArticleId IdType="pubmed">34312892</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung NHL, Chu DKW, Shiu EYC, Chan K-H, McDevitt JJ, Hau BJP, et al.. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nature medicine. 2020;26(5):676–80. doi: 10.1038/s41591-020-0843-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0843-2</ArticleId><ArticleId IdType="pmc">PMC8238571</ArticleId><ArticleId IdType="pubmed">32371934</ArticleId></ArticleIdList></Reference><Reference><Citation>Smereka J, Szarpak L. The use of personal protective equipment in the COVID-19 pandemic era. The American journal of emergency medicine. 2020;38(7):1529. doi: 10.1016/j.ajem.2020.04.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.04.028</ArticleId><ArticleId IdType="pmc">PMC7156949</ArticleId><ArticleId IdType="pubmed">32305157</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris C, Bénézit F, Geslin M, Polard E, Baldeyrou M, Turmel V, et al.. COVID-19 vaccine hesitancy among healthcare workers. Infectious Diseases Now. 2021;51(5):484–7. doi: 10.1016/j.idnow.2021.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8098031</ArticleId><ArticleId IdType="pubmed">33964486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, et al.. COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. American journal of epidemiology. 2021;190(1):161–75. doi: 10.1093/aje/kwaa191</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwaa191</ArticleId><ArticleId IdType="pmc">PMC7499478</ArticleId><ArticleId IdType="pubmed">32870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kursumovic E, Lennane S, Cook TM. Deaths in healthcare workers due to COVID‐19: the need for robust data and analysis. Anaesthesia. 2020;75(8):989. doi: 10.1111/anae.15116</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15116</ArticleId><ArticleId IdType="pmc">PMC7272944</ArticleId><ArticleId IdType="pubmed">32397005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrlich H, McKenney M, Elkbuli A. Protecting our healthcare workers during the COVID-19 pandemic. The American journal of emergency medicine. 2020;38(7):1527. doi: 10.1016/j.ajem.2020.04.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.04.024</ArticleId><ArticleId IdType="pmc">PMC7162741</ArticleId><ArticleId IdType="pubmed">32336585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay S, Baticulon RE, Kadhum M, Alser M, Ojuka DK, Badereddin Y, et al.. Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review. BMJ global health. 2020;5(12):e003097. doi: 10.1136/bmjgh-2020-003097</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2020-003097</ArticleId><ArticleId IdType="pmc">PMC7722361</ArticleId><ArticleId IdType="pubmed">33277297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn B, Brown L, Foege W, Gayle H, National Academies of Sciences E, Medicine. A framework for equitable allocation of COVID-19 vaccine. Framework for Equitable Allocation of COVID-19 Vaccine. 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33026758</ArticleId></ArticleIdList></Reference><Reference><Citation>Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, et al.. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. Journal of Virological Methods. 2021;297:114271. doi: 10.1016/j.jviromet.2021.114271</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114271</ArticleId><ArticleId IdType="pmc">PMC8393518</ArticleId><ArticleId IdType="pubmed">34461153</ArticleId></ArticleIdList></Reference><Reference><Citation>Elnasser Z, Obeidat H, Amarin Z, Alrabadi N, Jaradat A, Almomani R. Prevalence of COVID-19 among blood donors: The Jordan University of Science and Technology experience. Medicine. 2021;100(41). doi: 10.1097/MD.0000000000027537</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000027537</ArticleId><ArticleId IdType="pmc">PMC8519210</ArticleId><ArticleId IdType="pubmed">34731151</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatatbeh M. The battle against COVID-19 in Jordan: from extreme victory to extreme burden. Frontiers in Public Health. 2021;8:634022. doi: 10.3389/fpubh.2020.634022</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.634022</ArticleId><ArticleId IdType="pmc">PMC7873486</ArticleId><ArticleId IdType="pubmed">33585392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambhampati AK, O’Halloran AC, Whitaker M, Magill SS, Chea N, Chai SJ, et al.. COVID-19–associated hospitalizations among health care personnel—COVID-NET, 13 states, March 1–May 31, 2020. Morbidity and Mortality Weekly Report. 2020;69(43):1576. doi: 10.15585/mmwr.mm6943e3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6943e3</ArticleId><ArticleId IdType="pmc">PMC7659917</ArticleId><ArticleId IdType="pubmed">33119554</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa SF, Giavina-Bianchi P, Buss L, Mesquita Peres CH, Rafael MM, Dos Santos LGN, et al.. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and risk factors among oligo/asymptomatic healthcare workers: estimating the impact of community transmission. Clinical Infectious Diseases. 2021;73(5):e1214–e8. doi: 10.1093/cid/ciaa1845</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1845</ArticleId><ArticleId IdType="pmc">PMC7799298</ArticleId><ArticleId IdType="pubmed">33313659</ArticleId></ArticleIdList></Reference><Reference><Citation>Halili R, Bunjaku J, Gashi B, Hoxha T, Kamberi A, Hoti N, et al.. Seroprevalence of anti-SARS-CoV-2 antibodies among staff at primary healthcare institutions in Prishtina. BMC Infectious Diseases. 2022;22(1):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761334</ArticleId><ArticleId IdType="pubmed">35034617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataria Y, Cole M, Duffy E, de la Cena K, Schechter-Perkins EM, Bouton TC, et al.. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts. Scientific reports. 2021;11(1):9694. doi: 10.1038/s41598-021-89107-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89107-5</ArticleId><ArticleId IdType="pmc">PMC8102593</ArticleId><ArticleId IdType="pubmed">33958668</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash O, Solanki B, Sheth JK, Joshi B, Kadam M, Vyas S, et al.. Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study. BMJ open. 2021;11(1). doi: 10.1136/bmjopen-2020-044101</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044101</ArticleId><ArticleId IdType="pmc">PMC7786546</ArticleId><ArticleId IdType="pubmed">33402413</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al.. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health–Europe. 2021;1. doi: 10.1016/j.lanepe.2020.100013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2020.100013</ArticleId><ArticleId IdType="pmc">PMC7833818</ArticleId><ArticleId IdType="pubmed">34173621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf Z, Shaheen U, Iqbal MA, Qureshi MA, Rehman A, Qaisrani M. Seropositivity in PCR positive COVID-19 healthcare workers and its correlation with age, gender, anosmia and smoking. Age. 2020;77(22.91):100.</Citation></Reference><Reference><Citation>Müller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and risk factors of COVID-19 in healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence. Health policy and planning. 2022;37(4):505–13. doi: 10.1093/heapol/czab133</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapol/czab133</ArticleId><ArticleId IdType="pmc">PMC8689910</ArticleId><ArticleId IdType="pubmed">34726740</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y-H, Huang Q, Wang Y-Y, Zeng X-T, Luo L-S, Pan Z-Y, et al.. Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey. Military Medical Research. 2020;7:1–13. doi: 10.1186/s40779-019-0229-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-019-0229-2</ArticleId><ArticleId IdType="pmc">PMC7211983</ArticleId><ArticleId IdType="pubmed">32393381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kääriäinen S, Harjunmaa U, Hannila-Handelberg T, Ollgren J, Lyytikäinen O. Risk of COVID-19 in different groups of healthcare professionals between February 2020 and June 2021 in Finland: a register-based cohort study. Infect Prev Pract. 2023;5(3):100297. doi: 10.1016/j.infpip.2023.100297</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infpip.2023.100297</ArticleId><ArticleId IdType="pmc">PMC10406617</ArticleId><ArticleId IdType="pubmed">37560347</ArticleId></ArticleIdList></Reference><Reference><Citation>Batool H, Chughtai O, Khan MD, Chughtai AS, Ashraf S, Khan MJ. Seroprevalence of COVID-19 IgG antibodies among healthcare workers of Pakistan: a cross-sectional study assessing exposure to COVID-19 and identification of high-risk subgroups. BMJ Open. 2021;11(8):e046276. doi: 10.1136/bmjopen-2020-046276</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-046276</ArticleId><ArticleId IdType="pmc">PMC8370836</ArticleId><ArticleId IdType="pubmed">34400447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Rubio J, Navarro-López C, López-Nájera E, López-Nájera A, Jiménez-Díaz L, Navarro-López JD, et al.. A systematic review and meta-analysis of hospitalised current smokers and COVID-19. International Journal of Environmental Research and Public Health. 2020;17(20):7394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7601505</ArticleId><ArticleId IdType="pubmed">33050574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowsher R, Marczylo TH, Gooch K, Bailey A, Wright MD, Marczylo EL. Smoking and vaping alter genes related to mechanisms of SARS-CoV-2 susceptibility and severity: a systematic review and meta-analysis. Eur Respir J. 2024;64(1). doi: 10.1183/13993003.00133-2024</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00133-2024</ArticleId><ArticleId IdType="pmc">PMC11269771</ArticleId><ArticleId IdType="pubmed">38991709</ArticleId></ArticleIdList></Reference><Reference><Citation>Almadhi MA, Abdulrahman A, Alawadhi A, Rabaan AA, Atkin S, AlQahtani M. The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes. Scientific reports. 2021;11(1):5745. doi: 10.1038/s41598-021-84810-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84810-9</ArticleId><ArticleId IdType="pmc">PMC7952683</ArticleId><ArticleId IdType="pubmed">33707451</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudin L, Janvier F, Bylicki O, Dutasta F. ABO blood groups are not associated with the risk of acquiring SARS-CoV-2 infection in young adults. Haematologica. 2020;105(12):2841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716357</ArticleId><ArticleId IdType="pubmed">33256383</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan AT, Ucar AA, Malkoc A, Hu J, Buxton L, Tseng AW, et al.. ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review. Blood Res. 2023;58(3):138–44. doi: 10.5045/br.2023.2023122</Citation><ArticleIdList><ArticleId IdType="doi">10.5045/br.2023.2023122</ArticleId><ArticleId IdType="pmc">PMC10548287</ArticleId><ArticleId IdType="pubmed">37751922</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Garner R, Salehi S, La Rocca M, Duncan D. Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies. Annals of hematology. 2021;100:1123–32. doi: 10.1007/s00277-021-04489-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-021-04489-w</ArticleId><ArticleId IdType="pmc">PMC7939543</ArticleId><ArticleId IdType="pubmed">33686492</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift MD, Sampathkumar P, Breeher LE, Ting HH, Virk A. Mayo Clinic’s multidisciplinary approach to Covid-19 vaccine allocation and distribution. NEJM Catalyst Innovations in Care Delivery. 2021;2(1).</Citation></Reference><Reference><Citation>Schmidt H, Weintraub R, Williams MA, Miller K, Buttenheim A, Sadecki E, et al.. Equitable allocation of COVID-19 vaccines in the United States. Nature Medicine. 2021;27(7):1298–307. doi: 10.1038/s41591-021-01379-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01379-6</ArticleId><ArticleId IdType="pubmed">34007071</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academies of Sciences E, Medicine, Health, Medicine D, Board on Population H, Public Health P, et al.. The National Academies Collection: Reports funded by National Institutes of Health. In: Kahn B, Brown L, Foege W, Gayle H, editors. Framework for Equitable Allocation of COVID-19 Vaccine. Washington (DC): National Academies Press (US), Copyright 2020 by the National Academy of Sciences. All rights reserved.; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33026758</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H. Vaccine Rationing and the Urgency of Social Justice in the Covid-19 Response. Hastings Cent Rep. 2020;50(3):46–9. doi: 10.1002/hast.1113</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hast.1113</ArticleId><ArticleId IdType="pmc">PMC7283636</ArticleId><ArticleId IdType="pubmed">32468631</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>